Next Article in Journal
β-Defensins Coordinate In Vivo to Inhibit Bacterial Infections of the Trachea
Next Article in Special Issue
BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?
Previous Article in Journal / Special Issue
Therapeutic Vaccines for Genitourinary Malignancies
Article Menu

Export Article

Open AccessReview
Vaccines 2018, 6(3), 56;

Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy

1,2,* and 1,2,3,4
Division of Gynecologic Oncology, Department of Oncology, KU Leuven, 3000 Leuven, Belgium
Leuven Cancer Institute (LKI), 3000 Leuven, Belgium
Division of Gynecology & Obstetrics, UZ Leuven, 3000 Leuven, Belgium
Center for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek-Netherlands Cancer Institute (Avl-NKI) and University Medical Centra (UMC), 1066 CX Amsterdam, The Netherlands
Author to whom correspondence should be addressed.
Received: 13 July 2018 / Revised: 17 August 2018 / Accepted: 22 August 2018 / Published: 25 August 2018
(This article belongs to the Special Issue Therapeutic Vaccines and Cancer Immunotherapy)
PDF [809 KB, uploaded 25 August 2018]


Endometrial stromal sarcomas are a subtype of uterine sarcomas that are characterized by recurrent chromosomal translocations, resulting in the expression of tumor-specific fusion proteins that contribute to their tumorigenicity. These characteristics make the translocation breakpoints promising targets for immunotherapeutic approaches. In this review, we first describe the current knowledge about the classification of endometrial stromal sarcomas, and their molecular and genetic characteristics. Next, we summarize the available data on the use of translocation breakpoints as immunotherapeutic targets. Finally, we propose a roadmap to evaluate the feasibility of immunologic targeting of the endometrial stromal sarcoma-specific translocations in patients with recurrent disease. View Full-Text
Keywords: endometrial stromal sarcoma; recurrent chromosomal translocations; neoantigen; immunotherapy endometrial stromal sarcoma; recurrent chromosomal translocations; neoantigen; immunotherapy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Tuyaerts, S.; Amant, F. Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy. Vaccines 2018, 6, 56.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top